Compare BETR & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BETR | ADCT |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 538.7M | 484.4M |
| IPO Year | N/A | 2019 |
| Metric | BETR | ADCT |
|---|---|---|
| Price | $38.30 | $4.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $40.00 | $7.75 |
| AVG Volume (30 Days) | 517.9K | ★ 630.5K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | $54.06 | N/A |
| Revenue Next Year | $66.68 | $66.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $10.81 | $1.14 |
| 52 Week High | $94.06 | $4.98 |
| Indicator | BETR | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 55.60 | 61.38 |
| Support Level | $26.89 | $3.28 |
| Resistance Level | $41.23 | $4.32 |
| Average True Range (ATR) | 3.54 | 0.23 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 49.90 | 100.00 |
Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).